Novartis announces expiration of Tourmaline Bio tender offer
Basel, October 28 2025 – Novartis today announced that its previously announced tender offer (the “offer”) by Torino Merger…
Novartis showcases significant immunology advancements in ACR congress with new data in complex autoimmune diseases
Late-breaking positive Phase III data from ianalumab NEPTUNUS-1 and NEPTUNUS-2 trials in Sjögren’s disease to be presented Biomarker…
Novartis Cosentyx® meets primary and all secondary endpoints in Phase III trial in patients with polymyalgia rheumatica (PMR)
Cosentyx® (secukinumab) achieved statistically significant and clinically meaningful sustained remission vs placebo at Week 521Trial showed reduction in…
PSMAddition data show Novartis Pluvicto™ delays progression to end-stage prostate cancer
PluvictoTM plus standard of care (ARPI + ADT) significantly reduced risk of progression or death by 28% (HR…
Novartis to showcase transformative data in advanced prostate and early breast cancer at ESMO 2025
Key data from PSMAddition has been selected for a Presidential session; data to showcase the efficacy and safety…
One in four Indians faces silent genetic threat to heart health, shows study
In the Asia Pacific and Middle East region, two in three individuals (66%) skip routine heart tests, while…
AI Tools Are Spreading Medical Scams Online
In this week’s edition of InnovationRx, we look at AI medical scams, using machine learning to derive drugs…